Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Agoram · SciRah

Researcher profile · Semantic Scholar

B. Agoram

Share profile

B. Agoram — researcher profile on SciRah

h-index: 21
Works: 55
Citations: 3,074

Most-cited papers

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
R. Advani, I. Flinn, L. Popplewell, A. Forero +17 more
2018New England Journal of Medicine919 citations Open access
Semantic Scholar
Predicting the impact of physiological and biochemical processes on oral drug bioavailability.
B. Agoram, W. Woltosz, M. Bolger
2001Advanced Drug Delivery Reviews617 citations
Semantic Scholar
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
B. Sikic, N. Lakhani, A. Patnaik, Sumit A. Shah +26 more
2016Journal of Clinical Oncology476 citations Open access
Semantic Scholar
The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
B. Agoram, S. Martin, P. H. van der Graaf
2007Drug Discovery Today147 citations
Semantic Scholar
Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.
B. Agoram
2009British Journal of Clinical Pharmacology86 citations Open access
Semantic Scholar
The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.
D. Sallman, W. Donnellan, A. Asch, D. Lee +13 more
2019Journal of Clinical Oncology65 citations
Semantic Scholar
Targeting macrophage checkpoint inhibitor SIRPa for anticancer therapy.
Jie Liu, Seethu Xavy, S. Mihardja, Sharline Chen +7 more
2020JCI Insight61 citations Open access
Semantic Scholar
Once-Monthly Administration of Darbepoetin Alfa for the Treatment of Patients with Chronic Heart Failure and Anemia: A Pharmacokinetic and Pharmacodynamic Investigation
J. Cleland, J. T. Sullivan, S. Ball, J. Horowitz +6 more
2005Journal of Cardiovascular Pharmacology52 citations Open access
Semantic Scholar
Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency.
P. Aston, G. Derks, A. Raji, B. Agoram +1 more
2011Journal of Theoretical Biology51 citations Open access
Semantic Scholar
Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy
B. Agoram, A. Heatherington, M. Gastonguay
2006AAPS Journal50 citations Open access
Semantic Scholar
Methodologies for Quantitative Systems Pharmacology (QSP) Models: Design and Estimation
B. Ribba, H. P. Grimm, B. Agoram, M. Davies +5 more
2017CPT: Pharmacometrics & Systems Pharmacology44 citations Open access
Semantic Scholar
Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development.
B. Agoram, O. Demin
2011Drug Discovery Today42 citations
Semantic Scholar
A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.
G. Fisher, N. Lakhani, C. Eng, J. Hecht +14 more
202039 citations
Semantic Scholar
Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role.
B. Agoram, K. Aoki, S. Doshi, C. Gegg +4 more
2009Journal of Pharmacy and Science39 citations
Semantic Scholar
Population pharmacokinetics of darbepoetin alfa in healthy subjects.
B. Agoram, Liviawati Sutjandra, J. T. Sullivan
2007British Journal of Clinical Pharmacology37 citations Open access
Semantic Scholar
Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models
B. Agoram
2014CPT: Pharmacometrics & Systems Pharmacology33 citations Open access
Semantic Scholar
Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease.
P. Glossop, Christine A L Watson, David A. Price, Mark E. Bunnage +21 more
2011Journal of Medicinal Chemistry29 citations Open access
Semantic Scholar
A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.
N. Lakhani, A. Patnaik, J. Liao, J. Moroney +12 more
202027 citations
Semantic Scholar
THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS
R. Advani, N. Bartlett, S. Smith, M. Roschewski +16 more
2019Hematological Oncology26 citations
Semantic Scholar
Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.
P. Baverel, Meenakshi Jain, I. Stelmach, Dewei She +4 more
2015British Journal of Clinical Pharmacology25 citations Open access
Semantic Scholar
Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.
R. Advani, I. Flinn, L. Popplewell, A. Forero-Torres +11 more
201823 citations
Semantic Scholar
Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma
Neang S. Ly, Yanan Zheng, J. Griffiths, Rene Merwe +3 more
2020Journal of clinical pharmacology19 citations
Semantic Scholar
The application of mathematical modelling to the design of bispecific monoclonal antibodies
T. V. van Steeg, K. Bergmann, N. Dimasi, K. Sachsenmeier +1 more
2016mAbs19 citations Open access
Semantic Scholar
Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates
Meenakshi Jain, D. Doughty, Corbin Clawson, Xiaobai Li +3 more
2017International journal of clinical pharmacology and therapeutics18 citations Open access
Semantic Scholar
A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.
B. Sikic, N. Lakhani, A. Patnaik, Sumit A. Shah +16 more
201812 citations
Semantic Scholar
At the bench: the key role of PK–PD modelling in enabling the early discovery of biologic therapies
M. Penney, B. Agoram
2014British Journal of Clinical Pharmacology11 citations Open access
Semantic Scholar
A mathematical analysis of rebound in a target-mediated drug disposition model: I.Without feedback
P. Aston, G. Derks, B. Agoram, P. H. van der Graaf
2013Journal of Mathematical Biology11 citations Open access
Semantic Scholar
Biomarkers and biomeasures: key enablers for pharmacokinetic-pharmacodynamic modeling in drug discovery and development.
B. Agoram, P. H. van der Graaf
2012Bioanalysis11 citations
Semantic Scholar
Dose‐Exposure‐Response Relationship of the Investigational Anti‐Interleukin‐13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma
Paul G. Baverel, N. White, P. Vicini, M. O. Karlsson +1 more
2018Clinical pharmacology and therapy10 citations
Semantic Scholar
Pharmacokinetics of Hu5F9-G4, a first-in-class anti-CD47 antibody, in patients with solid tumors and lymphomas.
B. Agoram, Bing Wang, B. Sikic, N. Lakhani +5 more
201810 citations
Semantic Scholar
Analytical assay platforms for soluble target engagement biomarkers: old favorites and emerging technologies.
Joanne Goodman, B. Agoram
2013Bioanalysis10 citations
Semantic Scholar
S878 THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 IS ACTIVE AND WELL TOLERATED ALONE OR IN COMBINATION WITH AZACITIDINE IN AML AND MDS PATIENTS: INITIAL PHASE 1B RESULTS
D. Sallman, W. Donnellan, A. Asch, D. Lee +12 more
2019HemaSphere9 citations Open access
Semantic Scholar
A mathematical analysis of rebound in a target-mediated drug disposition model: II. With feedback
P. Aston, G. Derks, B. Agoram, P. H. van der Graaf
2014Journal of Mathematical Biology9 citations Open access
Semantic Scholar
A non-parametric method to analyse time-course of effect in the absence of pharmacokinetic data: application to inhaled bronchodilators.
B. Agoram, P. A. Milligan, P. H. van der Graaf
2008European Journal of Pharmaceutical Sciences8 citations
Semantic Scholar
Exposure-response analysis of tezepelumab in patients with severe asthma to guide phase 3 dose selection
Neang S. Ly, Yanan Zheng, J. Griffiths, R. van der Merwe +2 more
2018Clinical Problems7 citations
Semantic Scholar
Regulation of leukotriene and 5oxoETE synthesis and the effect of 5-lipoxygenase inhibitors: a mathematical modeling approach
T. Karelina, K. Zhudenkov, Oleg O. Demin, Dmitry V. Svetlichny +3 more
2012BMC Systems Biology7 citations Open access
Semantic Scholar
An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates
Kristopher D. Marjon, James Y. Chen, Jiaqi Duan, T. Choi +14 more
2019Blood6 citations Open access
Semantic Scholar
Book Review: ADME and Translational Pharmacokinetics/Pharmacodynamics of Therapeutic Proteins, by Honghui Zhou and Frank-Peter Theil John Wiley and Sons, Inc. 472 pp, hardcover ISBN: 978-1-118-89864-2
B. Agoram
2017CPT: Pharmacometrics & Systems Pharmacology5 citations Open access
Semantic Scholar
S867 THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 WITH RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS
R. Advani, N. Bartlett, Sonali M. Smith, M. Roschewski +16 more
2019HemaSphere2 citations Open access
Semantic Scholar
Translational Study of Cell Surface Proteins in Non-Hodgkin Lymphoma Patients Treated with the First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Rituximab
R. Maute, James Y. Chen, Kristopher D. Marjon, Jiaqi Duan +5 more
2019Blood2 citations Open access
Semantic Scholar
Evaluation of hyperglycosylated erythropoiesis stimulating proteins developed using glycoengineering
S. Elliott, K. Aoki, B. Agoram, D. Brankow +2 more
20062 citations
Semantic Scholar
Nonclinical drug development
C. Takimoto, M. Wick, B. Agoram, D. Jin
2022Atkinson's Principles of Clinical Pharmacology1 citations
Semantic Scholar
Pharmacokinetic (PK)-pharamcodynamic (PD) analysis and receptor occupancy data to support every other week maintenance dosing of magrolimab in combination with azacitidine in MDS/AML patients.
B. Agoram, C. Jin, R. Maute, C. Takimoto +2 more
20201 citations
Semantic Scholar
Development and evaluation of a population pharmacokinetic (PK) model for darbepoetin alfa in healthy subjects
B. Agoram, Liviawati Sutjandra, J. T. Sullivan
20051 citations
Semantic Scholar
Development of a pharmacokinetic pharmacodynamic (PKPD) model to predict onset of hemolytic anemia in (PEG)interferon/ribavirin treated hepatitis–C virus (HCV)‐infected patients
B. Agoram, R. Marino, S. George, N. Lam +1 more
20041 citations
Semantic Scholar
Contributors
D. Abernethy, B. Agoram, John M. Allen, Mark E. Arnold +82 more
2022Atkinson's Principles of Clinical Pharmacology0 citations
Semantic Scholar
2017 Reviewer Acknowledgment
C. Abdallah, D. Abernethy, D. Adler, S. Agarwal +162 more
2018CPT: Pharmacometrics & Systems Pharmacology0 citations Open access
Semantic Scholar
Methodologies for quantitative systems pharmacology (QSP) models
H. Grimm, B. Agoram, Davies, K. Gadkar +3 more
20170 citations
Semantic Scholar
Biopharmaceutics of NCEs and NBEs
B. Agoram, K. Sagawa, R. Shanker, S. Singh
20160 citations
Semantic Scholar
Agonistes de glucagon/glp-1 pour le traitement de l'obésité
B. Agoram, Madeleine Antonsson, Maria A. Bednarek, Nicole Burmeister +6 more
20130 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Takimoto×16
Invite
C. Takimoto — researcher profile on SciRah
Mark P. Chao×13
Invite
Mark P. Chao — researcher profile on SciRah
J. Volkmer×10
Invite
J. Volkmer — researcher profile on SciRah
James Y. Chen×7
Invite
James Y. Chen — researcher profile on SciRah

P. H. van der Graaf

×7

Invite

P. H. van der Graaf — researcher profile on SciRah

Invite

R. Majeti — researcher profile on SciRah

Invite

N. Lakhani — researcher profile on SciRah

Invite

A. Patnaik — researcher profile on SciRah

Invite

I. Flinn — researcher profile on SciRah

L. Popplewell×4

Invite

L. Popplewell — researcher profile on SciRah

Invite

J. Kline — researcher profile on SciRah

Invite

T. Tran — researcher profile on SciRah